Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation. (Q53938520)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9920144%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9920144%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

0 references

1 reference

based on heuristic

inferred from title

familial combined hyperlipidemia

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9920144%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9920144%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

author name string

D Zambón

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9920144%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

C Rodriguez-Villar

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9920144%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

M Vázquez

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9920144%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

C Sanllehy

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9920144%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

E Casals

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9920144%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

J M Sol

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9920144%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

G Hernández

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9920144%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

publication date

1 January 1999

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9920144%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9920144%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

48

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9920144%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9920144%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

47-54

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9920144%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

Familial lipoprotein disorders in patients with premature coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

Very low density lipoprotein overproduction in genetic forms of hypertriglyceridaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

Metabolic and genetic aspects of familial combined hyperlipidaemia with emphasis on low-density lipoprotein heterogeneity

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

Familial combined hyperlipidaemia linked to the apolipoprotein AI–CIII–AIV gene cluster on chromosome 11q23q–q24

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

Linkage of familial combined hyperlipidaemia to chromosome 1q21-q23

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

Nicotinic acid for the treatment of hyperlipoproteinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

HMG-CoA reductase inhibitors for treatment of hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

Fibric acids: effects on lipids and lipoprotein metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

Effect of apolipoprotein E polymorphism on the serum lipid response to a hypolipidemic diet rich in monounsaturated fatty acids in patients with hypercholesterolemia and combined hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

Treatment of combined hyperlipidemia with lovastatin versus gemfibrozil: a comparison study

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate.

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

Plasma triglyceride determines structure-composition in low and high density lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

Metabolism of apolipoprotein B in large triglyceride-rich very low density lipoproteins of normal and hypertriglyceridemic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

Serum lipoproteins, apolipoproteins and very low density lipoprotein subfractions during 6-month fibrate treatment in primary hypertriglyceridaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

Effect of gemfibrozil on the concentration and composition of very low density and low density lipoprotein subfractions in hypertriglyceridemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

Effects of gemfibrozil on low-density lipoprotein particle size, density distribution, and composition in patients with type II diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

Effects of lovastatin on the levels, structure, and atherogenicity of VLDL in patients with moderate hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

Effect of simvastatin on the apparent size of LDL particles in patients with type IIB hyperlipoproteinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

The effect of lovastatin treatment on low-density lipoprotein hydrated density distribution and composition in patients with intermittent claudication and primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

Combination drug therapy for familial combined hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

Management of primary mixed hyperlipidemia with lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

Familial combined hyperlipidemia and abnormal lipoprotein lipase

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990009-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0026-0495(99)90009-4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9920144%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9920144%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53938520&oldid=1527023964"